In conclusion, LINC00641 can be used as a tumor suppressor of prostate cancer, which can increase the expression of VGLL4 and inhibit the proliferation and invasion of prostate cancer cells by competitively binding miR-365a-3p through the ceRNA mechanism. Here, VGLL4 is linked to prostate cancer.